0000897069-23-001052.txt : 20230802 0000897069-23-001052.hdr.sgml : 20230802 20230802170637 ACCESSION NUMBER: 0000897069-23-001052 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230731 FILED AS OF DATE: 20230802 DATE AS OF CHANGE: 20230802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peyer James CENTRAL INDEX KEY: 0001843594 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 231136822 MAIL ADDRESS: STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC. STREET 2: 1405 RESEARCH BLVD., STE. 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 form4.xml X0508 4 2023-07-31 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001843594 Peyer James 228 PARK AVENUE S. #66643 NEW YORK NY 10003 true true false Common Stock 2023-07-31 4 D 0 1587302 1.26 D 3653120 I See footnote Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and Cambrian BioPharma Inc. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended. These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. /s/ James Peyer 2023-08-02